Skip to main content
ASTAL LABORATORIES LIMITED logo

ASTAL LABORATORIES LIMITED — Investor Relations & Filings

Ticker · 512600 ISIN · INE307N01014 LEI · 8945004HO2WCBQ0CJ976 BSE.NS Manufacturing
Open in API
Filings indexed 443 across all filing types
Latest filing 2024-11-12 Regulatory Filings
Country IN India
Listing BSE.NS 512600

About ASTAL LABORATORIES LIMITED

https://miel.co.in/

Astal Laboratories Limited is a pharmaceutical organization engaged in the development, manufacturing, and marketing of a diverse range of pharmaceutical formulations. The company's product portfolio encompasses various dosage forms, including tablets, capsules, liquid orals, and topical preparations. It operates across several therapeutic categories, such as anti-infectives, analgesics, and gastrointestinal treatments. Astal Laboratories prioritizes quality control and adheres to established manufacturing standards to ensure the safety and efficacy of its products. The company focuses on providing accessible healthcare solutions through a robust distribution network and a commitment to research-driven formulation development.

Recent filings

Filing Released Lang Actions
Submission of unaudited financial results for the quarter ended 30th September 2024.
Regulatory Filings
2024-11-12 English
Intimation of outcome of Board Meeting held on 12th November 2024.
Regulatory Filings
2024-11-12 English
Astal Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2024 ,inter alia, to consider and approve the the unaudited standalone ....
Regulatory Filings
2024-11-06 English
Intimation of Outcome of the Meeting with Investor
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the Deputy Manager of BSE Limited, informing about a meeting held with an analyst/institutional investor. It explicitly states that no Unpublished Price Sensitive Information (UPSI) was shared. The letter references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. The content is an announcement of a meeting with investors and does not contain financial results, detailed presentations, or reports. It is a regulatory disclosure about investor meetings, which fits best under Regulatory Filings (RNS) as it is a compliance-related announcement without substantive financial data or report content.
2024-10-23 English
Submission of Intimation of Lost of Share Certificate received from RTA.
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to the stock exchange (BSE Limited) regarding the loss of share certificates and the issuance of duplicate share certificates. It references SEBI regulations and circulars related to share certificate handling. The content is an official notification about a specific corporate action concerning share certificates, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial data. This type of document fits the category of Regulatory Filings (RNS), as it is a compliance-related announcement that does not fall into more specific categories like share issue or capital change (SHA) or director dealings (DIRS). The document length is short and focused on regulatory compliance information.
2024-10-17 English
Submission of Intimation of Acquisition of Pharmaceutical Ingredient Manufacturing Plant.
Capital/Financing Update Classification · 95% confidence The document is an official communication addressed to the Deputy Manager of BSE Limited, informing about the acquisition of a Pharmaceutical Intermediates Manufacturing Plant by Astal Laboratories Limited. It references Regulation 30 of the Listing Regulations and a SEBI circular, which typically govern disclosures related to material events or corporate actions. The content details the acquisition event, including investment amount, nature of consideration, and expected benefits. The document is relatively short (3254 characters) and serves as an announcement of a corporate event rather than a full financial report or detailed analysis. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as acquisitions.
2024-10-16 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.